Julie Wolf Selected Research

Neoplasms (Cancer)

2/2012	The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy.
1/2010	Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells.
7/2007	Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
12/2006	Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
8/2006	Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Julie Wolf Research Topics

Disease

5	Neoplasms (Cancer) 02/2012 - 08/2006
3	Adenocarcinoma 01/2020 - 07/2007
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2012 - 08/2006
3	Exanthema (Rash) 03/2009 - 08/2006
3	Diarrhea 03/2009 - 08/2006
2	Pancreatic Neoplasms (Pancreatic Cancer) 12/2017 - 07/2007
1	Genomic Instability 01/2020
1	Injection Site Reaction 01/2018
1	Cellulitis 12/2017
1	Uveal melanoma 01/2010
1	Melanoma (Melanoma, Malignant) 01/2010
1	Sepsis (Septicemia) 12/2006
1	Fatigue 03/2006

Drug/Important Bio-Agent (IBA)

5	Erlotinib Hydrochloride (CP 358,774)FDA Link 02/2012 - 08/2006
4	Gemcitabine FDA Link 01/2020 - 03/2006
2	130-nm albumin-bound paclitaxelIBA 01/2020 - 12/2017
2	VaccinesIBA 01/2018 - 01/2010
2	Paclitaxel (Taxol)FDA LinkGeneric 12/2017 - 12/2006
1	Histones (Histone)IBA 01/2020
1	Lysine (L-Lysine)FDA Link 01/2020
1	MethyltransferasesIBA 01/2020
1	Heparin (Liquaemin)FDA LinkGeneric 12/2017
1	AnticoagulantsIBA 12/2017
1	VimentinIBA 02/2012
1	Cadherins (E-Cadherin)IBA 02/2012
1	Biomarkers (Surrogate Marker)IBA 02/2012
1	Proteins (Proteins, Gene)FDA Link 02/2012
1	Peptides (Polypeptides)IBA 01/2010
1	HLA-A Antigens (HLA-A)IBA 01/2010
1	Histocompatibility Antigens Class IIIBA 01/2010
1	SmokeIBA 03/2009
1	Carboplatin (JM8)FDA LinkGeneric 12/2006
1	Biological ProductsIBA 12/2006
1	Pharmaceutical PreparationsIBA 08/2006
1	NucleosidesIBA 03/2006
1	4'-thio-arabinofuranosylcytosineIBA 03/2006

Therapy/Procedure

2	Therapeutics 12/2017 - 02/2012
1	Subcutaneous Injections 12/2017